Epidemiological studies in idiopathic pulmonary fibrosis: Pitfalls in methodologies and data interpretation

European Respiratory Review

Volumn 24, Issue 137, 2015, Pages 436-444

  Caminati, Antonella ^a   Madotto, Fabiana ^b   Cesana, Giancarlo ^b   Conti, Sara ^b   Harari, Sergio ^a  

^a IRCCS MULTIMEDICA   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NINTEDANIB; PIRFENIDONE;

ASIAN; EUROPEAN; FIBROSING ALVEOLITIS; HEALTH CARE SYSTEM; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; LUNG FIBROSIS; METHODOLOGY; MORBIDITY; MORTALITY; PREVALENCE; PROGNOSIS; REVIEW; SOCIAL STATUS; SYSTEMATIC REVIEW; CLASSIFICATION; EPIDEMIOLOGY; FACTUAL DATABASE; IDIOPATHIC PULMONARY FIBROSIS; INTERNATIONAL CLASSIFICATION OF DISEASES; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR;

DATABASES, FACTUAL; EPIDEMIOLOGIC RESEARCH DESIGN; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; INCIDENCE; INTERNATIONAL CLASSIFICATION OF DISEASES; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84940660726     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.0040-2015     Document Type: Review

References (43)

1. Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183: 788–824.
2. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 431–440.
3. King TE Jr., Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet 2011; 378: 1949–1961.
4. Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011; 377: 1760–1769.
5. King TE Jr., Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2083–2092.
6. Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011; 365: 1079–1087.
7. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 2014; 370: 2071–2082.
8. Coultas DB, Hubbard R. Epidemiology of idiopathic pulmonary fibrosis. In: Lynch JP. Idiopathic Pulmonary Fibrosis. New York, Taylor & Francis, 2003; pp. 1–30.
9. Olson AL, Swigris JJ, Lezotte DC, et al. Mortality from pulmonary fibrosis increased in the United States from 1992 to 2003. Am J Respir Crit Care Med 2007; 176: 277–284.
10. Cherniack RM, Colby TV, Flint A, et al. Quantitative assessment of lung pathology in idiopathic pulmonary fibrosis. The BAL Cooperative Group Steering Committee. Am Rev Respir Dis 1991; 144: 892–900.
11. Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994; 150: 967–972.
12. Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174: 810–816.
13. Fernández Pérez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest 2010; 137: 129–137.
14. Raghu G, Chen SY, Yeh WS, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001–11. Lancet Respir Med 2014; 2: 566–572.
15. Kolek V. Epidemiology of cryptogenic fibrosing alveolitis in Moravia and Silesia, in the period 1981–1990. Internista 1995; 3: 105–108.
16. Thomeer M, Demedts M, Vandeurzen K. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg 2001; 56: 163–172.
17. Thomeer MJ, Costabel U, Rizzato G, et al. Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J 2001; 18: Suppl. 32, 114s–118s.
18. Hodgson U, Laitinen T, Tukiainen P. Nationwide prevalence of sporadic and familial idiopathic pulmonary fibrosis: evidence of founder effect among multiplex families in Finland. Thorax 2002; 57: 338–342.
19. von Plessen C, Grinde O, Gulsvik A. Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respir Med 2003; 97: 428–435.
20. Xaubet A, Ancochea J, Morell F, et al. Report on the incidence of interstitial lung diseases in Spain. Sarcoidosis Vasc Diffuse Lung Dis 2004; 21: 64–70.
21. Tinelli C, De Silvestri A, Richeldi L, et al. The Italian register for diffuse infiltrative lung disorders (RIPID): a four-year report. Sarcoidosis Vasc Diffuse Lung Dis 2005; 22: Suppl. 1, S4–S8.
22. Karakatsani A, Papakosta D, Rapti A, et al. Epidemiology of interstitial lung diseases in Greece. Respir Med 2009; 103: 1122–1129.
23. Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61: 980–985.
24. Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011; 66: 462–467.
25. Agabiti N, Porretta MA, Bauleo L, et al. Idiopathic pulmonary fibrosis (IPF) incidence and prevalence in Italy. Sarcoidosis Vasc Diffuse Lung Dis 2014; 31: 191–197.
26. Ohno S, Nakaya T, Bando M, et al. Idiopathic pulmonary fibrosis – results from a Japanese nationwide epidemiological survey using individual clinical records. Respirology 2008; 13: 926–928.
27. Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 2014; 190: 773–779.
28. Kaunisto J, Salomaa ER, Hodgson U, et al. Idiopathic pulmonary fibrosis – a systematic review on methodology for the collection of epidemiological data. BMC Pulm Med 2013; 13: 53.
29. Hutchinson J, Fogarty A, Hubbard R, et al. Global incidence and mortality of idiopathic pulmonary fibrosis: A systematic review. Eur Respir J 2015; 46: 795–806.
30. Behr J, Kreuter M, Hoeper MM, et al. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry. Eur Respir J 2015; 46: 186–196.
31. Mannino DM, Etzel RA, Parrish RG. Pulmonary fibrosis deaths in the United States, 1979–1991. An analysis of multiple-cause mortality data. Am J Respir Crit Care Med 1996; 153: 1548–1552.
32. Hyldgaard C, Hilberg O, Muller A, et al. A cohort study of interstitial lung diseases in central Denmark. Respir Med 2014; 108: 793–799.
33. Musellim B, Okumus G, Uzaslan E, et al. Epidemiology and distribution of interstitial lung diseases in Turkey. Clin Respir J 2014; 8: 55–62.
34. Lai CC, Wang CY, Lu HM, et al. Idiopathic pulmonary fibrosis in Taiwan – a population-based study. Respir Med 2012; 106: 1566–1574.
35. Hutchinson JP, McKeever TM, Fogarty AW, et al. Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century. Ann Am Thorac Soc 2014; 11: 1176–1185.
36. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000; 161: 646–664.
37. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165: 277–304.
38. Boyle P, Parkin DM. Statistical methods for registries. In: Breslow NE, Day NE. Statistical Methods in Cancer Research. Lyon, International Agency for Research on Cancer, 1980.
39. Nalysnyk L, Cid-Ruzafa J, Rotella P, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012; 21: 355–361.
40. Baumgartner KB, Samet JM, Coultas DB, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Collaborating Centers. Am J Epidemiol 2000; 152: 307–315.
41. Miyake Y, Sasaki S, Yokoyama T, et al. Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan. Ann Occup Hyg 2005; 49: 259–265.
42. Lederer DJ, Arcasoy SM, Barr RG, et al. Racial and ethnic disparities in idiopathic pulmonary fibrosis: a UNOS/ OPTN database analysis. Am J Transplant 2006; 6: 2436–2442.
43. Panos RJ, Mortenson RL, Niccoli SA, et al. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med 1990; 88: 396–404.